Peter Johannes Holst

Company: HERVolutions Therapeutics

Job title: Chief Scientific Officer

Seminars:

Targeting Cancer & Senescence Associated HERVs With mRNA & Adenovirus Encoded Antigens 12:30 pm

Discussing human endogenous retroviruses (HERVs) as emerged as possible immunotherapeutic targets for cancer and cell senescence associated diseases Reviewing how HERVOLUTION have developed mRNA and viral vector delivered HERV antigens forming HERV-like-particles within transduced cells Examining unique immunostimulatory mutations and viral chimerism allows effective break of immunological tolerance and anti-cancer and senolytic efficacyRead more

day: Day Two